{"id":247784,"date":"2026-11-19T19:23:40","date_gmt":"2026-11-20T01:23:40","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/11\/new-immunotherapy-drugs-target-two-evasive-cancer-driving-proteins"},"modified":"2026-11-19T19:23:40","modified_gmt":"2026-11-20T01:23:40","slug":"new-immunotherapy-drugs-target-two-evasive-cancer-driving-proteins","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/11\/new-immunotherapy-drugs-target-two-evasive-cancer-driving-proteins","title":{"rendered":"New immunotherapy drugs target two evasive cancer-driving proteins"},"content":{"rendered":"\n<p>Researchers have shown in mice that designer antibodies can curb the growth of tumors by targeting two of cancer\u2019s most infamous offenders\u2014the proteins RAS and p53, which are mutated in many tumors but have largely defied drug development efforts. If their promise holds up in clinical trials, such drugs could make it possible to unleash the body\u2019s immune system on hard-to-treat cancers including pancreatic and ovarian.<\/p>\n<p>\u201cIt\u2019s exciting,\u201d says immunologist Jon Weidanz of the University of Texas, Arlington, who co-founded a company that works on similar immunotherapies, called bispecific antibodies. The new drugs can lock onto a few snippets of p53 or RAS jutting out from a tumor cell\u2019s surface\u2014and then trigger immune cells to attack them. \u201cThe therapies have the potential to work when there\u2019s a really low number of the target on cells. That is a big deal,\u201d says Weidanz, who wrote a <a href=\"https:\/\/science.sciencemag.org\/cgi\/doi\/10.1126\/science.abg5568\">commentary<\/a> accompanying the papers.<\/p>\n<p>P53 is a tumor suppressor, and the intact protein helps healthy cells repair DNA\u2014or self-destruct if the damage can\u2019t be fixed. When p53 is turned off in tumors, they can grow unchecked. But targeting p53 with drugs is difficult, because restoring its activity is much harder than inhibiting its activity or turning off its production\u2014more typical drug strategies against misbehaving proteins.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Researchers have shown in mice that designer antibodies can curb the growth of tumors by targeting two of cancer\u2019s most infamous offenders\u2014the proteins RAS and p53, which are mutated in many tumors but have largely defied drug development efforts. If their promise holds up in clinical trials, such drugs could make it possible to unleash [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-247784","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/247784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=247784"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/247784\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=247784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=247784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=247784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}